CD5 and cancer: Similarly, ex vivo treatment with a blocking anti-CD5 (clone 53–7.3) mAb increased the killing capacity of CD8+ T lymphocytes of mouse cancer (breast) cells concomitant with increased expression of markers for both T cell activation (i.e., CD69) and AICD (i.e., Fas, FasL) [68].